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Population-Level Decline in BMI and Systolic Blood Pressure
Following Mass HIV Treatment: Evidence from Rural
KwaZulu-Natal
Pascal Geldsetzer1, Andrea B. Feigl1,2, Frank Tanser3,4, Dickman Gareta3, Deenan Pillay3,4, and Till B€arnighausen1,3,5
Objective: Clinic-based studies have shown that patients with human immunodeficiency virus (HIV) gain
weight after initiation of antiretroviral therapy (ART). This study aimed to determine whether the scale-up
of ART was associated with a population-level increase in body mass index (BMI) and blood pressure
(BP) in a community with high HIV and obesity prevalence.
Methods: A household survey was conducted in rural KwaZulu-Natal before ART scale-up (in 2004) and
when ART coverage had reached 25% (in 2010). Anthropometric data was linked with HIV surveillance data.
Results: Mean BMI decreased in women from 29.9 to 29.1 kg/m2 (P 5 0.002) and in men from 24.2 to
23.0 kg/m2 (P < 0.001). Similarly, overweight and obesity prevalence declined significantly in both sexes.
Mean systolic BP decreased from 123.0 to 118.2 mm Hg (P < 0.001) among women and 128.4 to
123.2 mm Hg (P < 0001) among men.
Conclusions: Large-scale ART provision is likely to have caused a decline in BMI at the population level,
because ART has improved the survival of those with substantial HIV-related weight loss. The ART scale-
up may have created an unexpected opportunity to sustain population-level weight loss in communities
with high HIV and obesity prevalence though targeted lifestyle and nutrition interventions.
Obesity (2016) 00, 00–00. doi:10.1002/oby.21663
Introduction
Noncommunicable diseases (NCDs) are rapidly replacing infectious
diseases as the leading causes of the disease burden in sub-Saharan
Africa (SSA) (1,2). Yet the human immunodeficiency virus (HIV)
epidemic continues to take a considerable toll in SSA, where
approximately 26 million people were living with HIV in 2014 (3).
More recently, there has been an increasing policy and research
interest in the relationship between the HIV epidemic in SSA and
the rise in NCDs, in particular cardiovascular disease (CVD) (4).
This relationship is complex as the HIV infection itself, the treat-
ment for HIV, and the timing of treatment during the disease course
are all likely to affect the risk of CVD. While there is evidence that
people living with HIV (PLHIV) have a higher risk of CVD than
HIV-negative individuals (5), a possibly far more important driver
of the epidemiological transition from acute infectious diseases to
chronic NCDs in SSA is the massive scale-up of antiretroviral
therapy (ART) (6). The survival of HIV-positive populations into
old age due to ART will likely reveal CVD burdens previously
“hidden” by high HIV mortality (6,7). In addition, there has been a
growing concern that several antiretroviral drugs have side effects
that increase patients’ risk of developing CVD. A systematic review
found that PLHIV on ART had a higher risk of CVD than PLHIV
not on ART, and the risk of developing CVD rose with increasing
duration on ART (5). However, the effect of ART on CVD risk is
likely to vary substantially between different antiretroviral drugs
(5,8,9) and with the timing of ART initiation (as there is some evi-
dence that earlier initiation of ART may decrease CVD risk (10)).
1 Department of Global Health & Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. Correspondence: Till B€arnighausen
(tbaernig@hsph.harvard.edu) 2 Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA 3 Africa Health
Research Institute, Mtubatuba, South Africa 4 Institute of Epidemiology and Health Care, University College London, London, UK 5 Institute of Public
Health, Faculty of Medicine, Heidelberg University, Heidelberg, Germany.
Funding agencies: The research infrastructure at the Africa Health Research Institute (AHRI) was funded by the UK medical research charity Wellcome Trust. TB received
funding from the Alexander von Humboldt Foundation through the Alexander von Humboldt professor award and from NICHD of NIH (R01-HD084233) and NIAID of NIH
(R01-AI124389 and R01-AI112339).
Disclosure: The authors declare no conflicts of interest.
Author contributions: TB conceived the study. PG and ABF conducted the analyses. PG drafted the manuscript. PG and ABF contributed equally. All authors critically
revised and approved the final version of the manuscript.
Additional Supporting Information may be found in the online version of this article.
Received: 16 February 2016; Accepted: 26 July 2016; Published online 00 Month 2016. doi:10.1002/oby.21663
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
www.obesityjournal.org Obesity | VOLUME 00 | NUMBER 00 | MONTH 2016 1
Original Article
EPIDEMIOLOGY/GENETICS
Obesity
Weight gain following ART initiation is well documented (11-15).
However, the weight gain on ART is likely to follow a prior weight
loss. Weight loss, including severe wasting, is part of the natural
history of HIV infection (16). This study focuses on the first 7 years
of ART scale-up in SSA (between 2004 and 2010). Because treat-
ment guidelines during this period recommended ART only for
those whose HIV infection was relatively advanced, and because a
large proportion of PLHIV enrolled in care long after their disease
stage had advanced to the point of ART eligibility (17), many
PLHIV were likely to have lost significant amounts of weight by
the time they were initiated on ART. By greatly extending the life
expectancy of these patients, ART is likely to have increased the
proportion of individuals in the population who had lost weight due
to HIV. It is unknown how rapidly and to what degree these ART
patients regained the weight they had lost or indeed if their weight
on ART eventually exceeded their weight at the time of infection.
A recent systematic review found that ART patients tended to have
higher blood pressure (BP) and increased hypertension risk com-
pared to HIV-positive patients not on ART (18). In addition, there is
evidence that antiretroviral drugs directly interfere with the physio-
logical mechanism of BP regulation by damaging the endothelial
lining of blood vessels (19,20). Clinic- and laboratory-based studies,
however, are unable to show how the scale-up of ART has affected
BP and hypertension risk at the population level.
The distinct advantage of examining the relationship between ART and
body mass index (BMI) in a population-based rather than clinic-based
study is that it is possible to determine the population “net effect” of
ART on weight. This net effect consists of two individual-level effects
of ART: (1) a biological effect, the weight gain following ART initia-
tion, and (2) a compositional effect, due to the increased survival of
HIV-positive people in advanced disease stages, who are likely to have
lost weight due to HIV infection. In addition, in a population-based
study, it is possible to study trends in BMI (and BP) in the HIV-negative
population, which provides insight into the population’s secular trends
in cardiovascular risk independent of HIV infection and ART.
This study was carried out in a community with a very high prevalence of
both HIV and obesity in rural KwaZulu-Natal, South Africa (6,21). Using
data from two population-based anthropometric surveys—one conducted
prior to the first HIV patients receiving ART in the area and the other
when estimated ART coverage in the area had reached 25% (22)—we
aimed to determine (1) the association between the ART scale-up and
BMI and BP at the population level, and (2) the secular trend in BMI and
BP in the HIV-negative population.
Methods
Study setting
The two anthropometric surveys were conducted in the Africa Health
Research Institute’s surveillance area, which is located in the largely
rural Hlabisa subdistrict of uMkhanyakude district in KwaZulu-Natal,
South Africa. The UMkhanyakude district is one of the poorest dis-
tricts in South Africa (23). The surveillance population consists of an
open cohort of more than 100,000 individuals. HIV prevalence in the
surveillance area was 22% in 2004, the year of the first anthropometric
survey, and 29% in 2010, when the second anthropometric survey was
conducted (Figure 1) (22). The HIV surveillance which generated this
HIV data is described in detail elsewhere (24).
Study design
We conducted two cross-sectional anthropometric surveys, one
before ART scale-up in 2004 and one in 2010 when an estimated
25% of HIV-positive individuals in the surveillance area were on
ART (Figure 1) (22). In both surveys we measured weight, height,
and BP using the WHO STEPS protocol (25). We selected a random
sample of 30 subareas within the Africa Health Research Institute’s
surveillance area for the anthropometric survey in 2004. For this
analysis, the same 30 subareas were chosen for the data from the
2010 anthropometric survey. Eligibility criteria for participation in
the surveys were (1) being a resident household member in one of
the sampled subareas, and (2) being aged between 25 and 49 years
for women and 25 and 54 years for men.
Data from the anthropometric surveys was matched with individuals’
HIV and ART status from the Africa Health Research Institute’s HIV
surveillance data. The HIV surveillance is conducted through annual
household visits, during which all adult household members are
offered an HIV test. Within a 5-year period, about 80% of the individ-
uals in this open cohort consent to HIV testing (26). If a household
member consents to an HIV test, a small finger prick blood sample is
taken. HIV status is then assessed by an enzyme-linked immunosor-
bent assay (ELISA) of EDTA anticoagulated blood samples in the
Africa Health Research Institute’s virology laboratory, using a HIV-1/
HIV-2 ELISA assay (Vironostika; Organon Taknika, Boxtel, The
Netherlands). In all HIV-positive samples, confirmatory HIV testing
was carried out. None of the participants in either the 2004 or the
2010 survey had discordant HIV test results. Ethical approval for the
anthropometric survey and HIV surveillance was granted by the Bio-
Medical Ethics Committee of the University of KwaZulu-Natal.
Definitions of overweight, obesity, and
hypertension
We defined overweight or obesity as a BMI 25.0 kg/m2 and obe-
sity as a BMI 30.0 kg/m2. Following the guidelines of the Euro-
pean Society of Cardiology (27), stage 1 hypertension was defined
as a systolic BP (sBP) 140 mm Hg and/or a diastolic BP (dBP)
Figure 1 Human immunodeficiency virus (HIV) prevalence and antiretroviral therapy
(ART) coverage among the 15- to 49-year-old population in the study community.
ART coverage is the estimated percentage of people living with HIV aged 15 to 49
years who are on ART. [Color figure can be viewed at wileyonlinelibrary.com]
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90 mm Hg, and stage 2 hypertension was defined as sBP
160 mm Hg and/or dBP 100 mm Hg.
Statistical analysis
For both the 2004 and 2010 survey, we calculated the mean BMI,
mean sBP, and mean dBP, as well as the prevalence of overweight
and obesity and stage 1 and stage 2 hypertension. In sensitivity analy-
ses we adjusted for changes in the age composition of the population
between the two survey rounds. The statistical analysis was conducted
using Stata 13.0 (State Corporation, College Station, TX).
Results
For the 2004 survey, 3,000 individuals were contacted, of which 2,252
(75.1%) agreed to a height and weight measurement and 2,266 (75.5%) to
a BP measurement. For the 2010 survey, 4,608 were contacted and 2,088
(45.3%) agreed to a height and weight measurement and 2,584 (55.3%) to
BP measurement. Two hundred seventy-six individuals participated in
both surveys.
BMI and prevalence of overweight and obesity
Overweight and obesity prevalence is high among this population
and was markedly higher among women than men in both 2004 and
2010 (Tables 1 and 2). Among women, mean BMI decreased from
29.9 kg/m2 in 2004 to 29.1 kg/m2 in 2010 (P 5 0002); among
men, mean BMI decreased from 24.2 kg/m2 to 23.0 kg/m2
(P<0.001). Similarly, overweight and obesity prevalence decreased
in both sexes with the decline being more marked for men.
When stratified by HIV status, we found that mean BMI decreased for
women living with HIV from 28.2 to 27.1 kg/m2 (P 5 0026), but
there was no statistically significant change in women who were HIV-
negative and those with unknown HIV status. We also found no
statistically significant differences in the proportion of women with
overweight or obesity by HIV status except for a marginally signifi-
cant (P 5 0.061) decrease in the proportion of HIV-positive women
with overweight or obesity from 63.5% (95% CI: 58.2–68.7%) to
57.1% (53.2–61.1%). For men, BMI did not change among men living
with HIV but decreased among HIV-negative men from 24.2 to
23.0 kg/m2 (P 5 0.004) and among those with unknown HIV status
from 25.2 to 24.2 kg/m2 (P 5 0030). Both the proportion with over-
weight or obesity (BMI 25 kg/m2) and the proportion with obesity
(BMI 30 kg/m2) decreased significantly among HIV-negative men
from 32.4% to 23.8% and from 12.3% to 6.6%, respectively.
BP and prevalence of hypertension
In the population, mean sBP decreased significantly in both women
(from 123.0 to 118.2 mm Hg; P < 0.001) and men (from 128.4 to
123.2 mm Hg; P < 0.001). Mean dBP increased slightly in both
sexes, from 79.6 to 81.4 mm Hg (P < 0.001) in women and from
79.0 to 80.7 mm Hg (P 5 0.005) in men. When stratified by HIV
status, mean sBP decreased between 2004 and 2010 among all three
groups (HIV-positive, HIV-negative, and unknown HIV status) in
both sexes. Mean dBP, on the other hand, increased slightly among
HIV-negative women, women with an unknown HIV status, and
HIV-negative men. There was no significant change in the propor-
tion of adults with hypertension (stage 1 or 2 hypertension) or stageTA
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2 hypertension in the aggregate population nor when stratified by
sex and HIV status (Supporting Information Table S1).
The results presented in Tables 1 and 2 do not change substantially
when adjusting for changes in the age composition of the population
between the two survey rounds.
Weight and BP by ART status
Stratifying the sample living with HIV in 2010 by ART status (Table 3),
we find that mean BMI was higher among those not on ART (ART-)
than those on ART (ART1) for both men and women. In addition, the
proportion of ART- women with obesity was almost double that of
ART1 women (31.6% vs. 16.2%; P < 0.001). Differences in sBP and
dBP were only significant when adjusting for age with mean BP being
higher among ART- than ART1. There were no significant differences
in stage 1 and stage 2 hypertension between the ART- and ART1
populations.
We further disaggregated this cross-sectional sample by time to
ART initiation (for those ART- at the time of the 2010 survey) and
time since ART initiation (for those ART1 at the time of the 2010
survey). Figure 2 (data with confidence intervals [CIs] shown in
Supporting Information Table S1 and S2) depicts a general trend
among both men and women: mean BMI, prevalence of BMI
25 kg/m2 (overweight or obesity), and prevalence of BMI 30 kg/
m2 (obesity) decreased up until shortly after ART initiation and then
increased again with a higher duration on ART. Importantly, men
who initiated ART within 1 to 3 years after the survey tended to
fully recover their baseline BMI. In contrast, women tended not to
fully recover their baseline BMI, even 3-6 years after ART
initiation.
Discussion
In an HIV-hyperendemic rural community in KwaZulu-Natal,
South Africa, BMI decreased substantially in both sexes (by 0.8
BMI points among women and 1.2 BMI points among men) fol-
lowing the public-sector ART scale-up. Our results suggest that the
population-level decline in BMI among women was likely caused
by ART improving the survival of women living with HIV who
had suffered substantial weight loss due to HIV disease. Among
men, on the other hand, the population-level decrease in BMI
seems largely due to the decline in BMI among those who were
HIV-negative. These findings are plausible as the HIV treatment
guidelines in place between 2004 and 2010 recommended starting
ART at a CD4-cell count <200 cells/mm3 or when the patient is in
WHO clinical stage IV (28). Thus, only the sickest HIV patients,
and therefore those with the most significant HIV-related weight
loss, were started on ART. Some of these patients died between
the two survey rounds and were therefore not surveyed in 2010. In
a recent study, we found that the ART scale-up in the study area
has been accompanied by a greater reduction in HIV-related mor-
tality among women than men (29). This observation implies that
men with substantial HIV-related weight loss were more likely to
have died (and therefore left the study population) despite the
availability of ART than their female counterparts, thus increasing
average BMI among HIV-positive men as compared to HIV-posi-
tive women.TA
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Another possible reason for the decline in BMI among women but
not men living with HIV is depicted in Figure 2. While this study is
limited by the cross-sectional nature of the data, both men and
women lose weight shortly before (and possibly for the first few
months after) initiating ART. Once initiated on ART, however,
those men who survive seem to regain their weight more quickly
than their female peers. One possible explanation for this trend is
food insecurity. In the same study area in rural KwaZulu-Natal,
Patenaude et al. found that ART had a positive causal effect on the
probability of any adult in the household missing a meal for finan-
cial reasons in the first 2 years after ART initiation (30). This effect
returned to zero between 2 and 4 years after ART initiation, a trend
that may be explained by the fact that the initial increase in food
insecurity is due to the high immediate financial costs of attending
ART care (31) (e.g., the cost of transport to the ART clinic and
time lost from work), while the beneficial effects of ART on
employment and income are delayed (32). It is plausible that men’s
meals are prioritized over that of women in food insecure house-
holds (33), which may allow men to regain their weight more
quickly after ART initiation compared with women.
Our 2010 BMI and BP findings for this poor rural community with
a very high prevalence of HIV were similar to national estimates
from the South African National Health and Nutrition Examination
Survey carried out in 2012. However, while mean BMI, overweight,
and obesity increased between 1998 and 2012 in South Africa
(34,35), it decreased in the study area between our 2004 and 2010
surveys. Both nationally and in this community, BMI, overweight,
and obesity were substantially higher among women than men in
both 2004 and 2010. The reasons for this large difference by sex are
still unclear and likely to be multifactorial (36). Importantly, how-
ever, while we found that mean BMI and the proportion of adults
with overweight and obesity decreased between 2004 and 2010 for
both sexes, the decline was more marked among men than women.
The discrepancy in the prevalence of overweight and obesity by sex
is therefore widening in this study population, which is also true for
South Africa as a whole (34,35). The finding that BMI decreased in
HIV-negative men from 24.2 to 23.0 kg/m2 (P 5 0004) while there
was no significant change among HIV-negative women suggests
that this divergence might be occurring independently of HIV status.
However, firm conclusions are limited by the possibility of a rela-
tionship between BMI and the probability of acquiring HIV.
We found that BP and hypertension prevalence were lower among
PLHIV than those not infected with HIV (Tables 1 and 2, Support-
ing Information Table S1). This could be a reflection of a higher BP
among individuals with an increased risk of acquiring HIV. An
alternative explanation is that HIV-related weight loss led to a
reduction in BP. In addition, we found that mean BP tended to be
higher among PLHIV with a longer duration on ART (Supporting
Information Tables S2 and S3). This may be explained by weight
gain on ART-induced damage to the endothelial lining (19,20).
However, unlike a recent systematic review, which found a positive
association between ART and BP (18), we found lower sBP and
dBP (after adjusting for age) among those on ART than PLHIV who
were not on ART.
This study has several limitations. First, refusal to participate in the
survey was comparatively high, which may have compromised the
representativeness of our sample. More specifically, if those who
declined to participate in the survey had a different BMI or BP than
those who participated, our results for both the 2004 and 2010 sur-
vey a would fail to be representative of the entire study population
at each time point. Furthermore, the refusal rate was higher in 2010
as compared with 2004. Thus, if the additional proportion of the
population who declined in 2010 as compared with 2004 had a dif-
ferent BMI and BP than those who participated in 2004, the changes
in BMI and BP between the two time points might be biased. Sec-
ond, the implications of this study for health policy would have
been strengthened if biomarkers of cardiovascular risk had been
assessed, such as biomarkers for diabetes and a lipid profile. How-
ever, such data was not available at the time of this analysis. Third,
TABLE 3 BMI and blood pressure (BP) in 2010 among people living with HIV, by ART status
Female Male
ART2 ART1 P ART2 ART1 P
n 399 210 132 62
Mean BMI (kg/m2) 28.0 (27.4–28.6) 25.5 (24.7–26.3) <0.001 22.5 (21.7–23.3) 21.4 (20.5–22.2) 0.074
Overweight or obesity (%)a 63.7 (58.9–68.4) 44.8 (38.0–51.5) <0.001 19.7 (12.9–26.5) 9.7 (2.3–17.0) 0.080
Obesity (%)b 31.6 (27.0–36.1) 16.2 (11.2–21.2) <0.001 6.1 (2.0–10.1) 1.6 (0.0–4.7) 0.170
n 450 256 158 81
Not adjusted for age
Mean systolic BP (mm Hg) 115.2 (113.6–116.8) 114.9 (112.9–116.9) 0.796 121.4 (119.1–123.6) 118.3 (115.5–121.2) 0.107
Mean diastolic BP (mm Hg) 80.0 (78.9–81.1) 78.8 (77.4–80.2) 0.208 79.6 (77.8–81.3) 77.0 (74.8–79.1) 0.077
Adjusted for age
Mean systolic BP (mm Hg) 115.9 (114.4–117.3) 113.7 (111.8–115.7) 0.086 121.90 (119.7–124.1) 117.3 (114.2–120.4) 0.020
Mean diastolic BP (mm Hg) 80.4 (79.4–81.5) 78.1 (76.7–79.5) 0.010 80.0 (78.3–81.7) 76.1 (73.7–78.5) 0.010
95% confidence intervals are shown in parentheses. Means were compared with the student’s t-test and proportions using a z-test.
None of the BMI comparisons changed significantly when adjusting for age. The numbers shown here are not adjusted for age.
aDefined as BMI 25 kg/m2.
bDefined as a BMI 30 kg/m2.
ART2, not on antiretroviral therapy at the time of the survey; ART1, on antiretroviral therapy at the time of the survey; BMI, body mass index.
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additional anthropometric data would have allowed further insight
into the relationship between ART and CVD at the population level.
However, a systematic review found that two important anthropo-
metric measures, waist circumference and waist-to-hip ratio, were
not stronger predictors of CVD than BMI (37). Fourth, this study
can only ascertain the association between the ART scale-up and
BMI and BP under the 2004 South African HIV treatment guide-
lines, which recommend the initiation of ART for PLHIV in
advanced disease stages (28). The association between ART scale-
up and BMI and BP may be substantially different when PLHIV in
earlier disease stages are eligible to receive ART.
Conclusion
There have been fears that the ART scale-up contributes to the rise
in CVD in SSA by increasing the prevalence of overweight and obe-
sity (6). We found that mean BMI, sBP, and the proportion of the
population with overweight and obesity decreased in the first years
of the public-sector ART scale-up in a rural community in
KwaZulu-Natal with high overall levels of both adiposity and HIV.
Overweight and obesity prevalence was lower around the time of
ART initiation and higher among those with a longer duration on
ART, similar to findings by Feigl et al. (38). Overall, our findings
suggest that the compositional effect of ART—increasing the sur-
vival of HIV-positive populations with large average weight loss—
outweighs the biological ART effect—increasing BMI following
ART initiation. Where overall levels of adiposity are high, as in the
community in which this study took place, the population net effect
of the ART scale-up on BMI provides an opportunity to intervene to
ensure that HIV-positive people on ART maintain healthy weight
levels in the long run. O
VC 2016 The Authors. Obesity published by Wiley Periodicals, Inc. on
behalf of The Obesity Society (TOS)
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